The protein encoded by this gene is a subunit of a heterodimer that, along with SUPT16H, forms chromatin transcriptional elongation factor FACT. FACT interacts specifically with histones H2A/H2B to effect nucleosome disassembly and transcription elongation. FACT and cisplatin-damaged DNA may be crucial to the anticancer mechanism of cisplatin. This encoded protein contains a high mobility group box which most likely constitutes the structure recognition element for cisplatin-modified DNA. This protein also functions as a co-activator of the transcriptional activator p63.
Structure specific recognition protein 1 has been shown to interact with NEK9. SSRP1 further interacts with transcriptional activator p63. SSRP1 enhances the activity of full-length p63, but it has no effect on the N-terminus-deleted p63 (DeltaN-p63) variant.
Kelley D, Stokes D, Perry R (1999). "CHD1 interacts with SSRP1 and depends on both its chromodomain and its ATPase/helicase-like domain for proper association with chromatin.". Chromosoma108 (1): 10–25. doi:10.1007/s004120050347. PMID10199952.
Spencer J, Baron M, Olson E (1999). "Cooperative transcriptional activation by serum response factor and the high mobility group protein SSRP1.". J. Biol. Chem.274 (22): 15686–93. doi:10.1074/jbc.274.22.15686. PMID10336466.
Orphanides G, Wu W, Lane W, Hampsey M, Reinberg D (1999). "The chromatin-specific transcription elongation factor FACT comprises human SPT16 and SSRP1 proteins.". Nature400 (6741): 284–8. doi:10.1038/22350. PMID10421373.
Wada T, Orphanides G, Hasegawa J, Kim D, Shima D, Yamaguchi Y et al. (2000). "FACT relieves DSIF/NELF-mediated inhibition of transcriptional elongation and reveals functional differences between P-TEFb and TFIIH.". Mol. Cell5 (6): 1067–72. doi:10.1016/S1097-2765(00)80272-5. PMID10912001.
Keller D, Zeng X, Wang Y, Zhang Q, Kapoor M, Shu H et al. (2001). "A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1.". Mol. Cell7 (2): 283–92. doi:10.1016/S1097-2765(01)00176-9. PMID11239457.
Yarnell A, Oh S, Reinberg D, Lippard S (2001). "Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin.". J. Biol. Chem.276 (28): 25736–41. doi:10.1074/jbc.M101208200. PMID11344167.
Santoro P, De Andrea M, Migliaretti G, Trapani C, Landolfo S, Gariglio M (2002). "High prevalence of autoantibodies against the nuclear high mobility group (HMG) protein SSRP1 in sera from patients with systemic lupus erythematosus, but not other rheumatic diseases.". J. Rheumatol.29 (1): 90–3. PMID11824977.
Keller D, Lu H (2003). "p53 serine 392 phosphorylation increases after UV through induction of the assembly of the CK2.hSPT16.SSRP1 complex.". J. Biol. Chem.277 (51): 50206–13. doi:10.1074/jbc.M209820200. PMID12393879.